苑东生物
(688513)
| 流通市值：69.22亿 | | | 总市值：69.22亿 |
| 流通股本：1.20亿 | | | 总股本：1.20亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 823,669,011.35 | 781,231,030.55 | 535,352,564.66 | 640,573,950.85 |
| 应收票据及应收账款 | 174,142,121.19 | 134,271,882.33 | 150,446,823.56 | 119,682,463.47 |
| 其中：应收票据 | 12,780,834.93 | 14,093,091.71 | 8,345,303.61 | 7,825,492.5 |
| 应收账款 | 161,361,286.26 | 120,178,790.62 | 142,101,519.95 | 111,856,970.97 |
| 应收款项融资 | 41,371,272.64 | 43,432,120.25 | 37,323,731.34 | 26,650,176.12 |
| 预付款项 | 15,895,108.63 | 8,782,042.81 | 14,232,171.71 | 17,774,001.55 |
| 其他应收款合计 | 1,204,516.46 | 659,830.97 | 629,599.98 | 427,383.58 |
| 存货 | 174,532,106.92 | 160,981,438.25 | 161,812,105.63 | 162,803,882.55 |
| 其他流动资产 | 8,901,471.95 | 11,730,599.96 | 6,303,408.71 | 5,243,080.35 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,903,687,347.18 | 1,882,871,229.64 | 1,786,564,487.15 | 1,700,289,166.53 |
| 非流动资产: | | | | |
| 长期股权投资 | 24,537,722.44 | 24,581,213.02 | 24,643,700.51 | 24,679,506.64 |
| 其他权益工具投资 | 10,000,000 | 10,000,000 | 10,000,000 | - |
| 其他非流动金融资产 | 48,000,000 | 46,500,000 | 46,500,000 | 38,500,000 |
| 固定资产 | 1,050,520,529.07 | 1,068,712,955.08 | 1,049,632,152.92 | 950,499,072.17 |
| 在建工程 | 205,412,904.89 | 186,255,273.04 | 167,022,005.92 | 240,761,185.52 |
| 无形资产 | 34,267,706.05 | 34,458,908.98 | 34,368,376.76 | 34,649,903.59 |
| 开发支出 | 58,952,690.67 | 49,997,045.04 | 45,929,260.51 | 45,126,245.7 |
| 长期待摊费用 | 4,438,408.78 | 4,919,676.44 | 5,465,982.44 | 2,361,169.02 |
| 递延所得税资产 | 8,249,429.02 | 8,569,997.26 | 6,553,278.04 | 6,534,616.15 |
| 其他非流动资产 | 26,304,206.73 | 29,887,995.38 | 39,292,110.13 | 42,037,066.98 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,470,683,597.65 | 1,463,883,064.24 | 1,429,406,867.23 | 1,385,148,765.77 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 3,374,370,944.83 | 3,346,754,293.88 | 3,215,971,354.38 | 3,085,437,932.3 |
| 流动负债: | | | | |
| 短期借款 | 161,086,535.84 | 180,948,021.5 | 131,100,438.89 | 131,077,997.19 |
| 应付票据及应付账款 | 174,898,650.98 | 180,937,660.86 | 157,159,921.97 | 169,358,141.4 |
| 其中：应付票据 | 43,683,937 | 45,800,823.69 | 37,353,377.61 | 53,166,632.54 |
| 应付账款 | 131,214,713.98 | 135,136,837.17 | 119,806,544.36 | 116,191,508.86 |
| 合同负债 | 44,220,122.65 | 31,982,310.83 | 28,399,196.58 | 17,824,841.69 |
| 应付职工薪酬 | 26,721,440.31 | 49,968,324.5 | 37,541,342.49 | 35,419,484.04 |
| 应交税费 | 22,714,924.78 | 15,867,172.46 | 22,360,884.28 | 16,744,251.41 |
| 其他应付款合计 | 225,843,526.71 | 195,942,610.22 | 177,080,044.42 | 160,785,722.67 |
| 一年内到期的非流动负债 | 2,933,333.33 | 2,933,333.33 | - | - |
| 其他流动负债 | 8,253,337.18 | 2,514,581.77 | 4,126,575.79 | 2,561,206.56 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 666,671,871.78 | 661,094,015.47 | 557,768,404.42 | 533,771,644.96 |
| 非流动负债: | | | | |
| 长期借款 | 39,635,090 | 39,600,000 | 44,033,000 | - |
| 递延收益 | 40,164,339.42 | 41,183,222.34 | 40,660,024.96 | 40,806,440.52 |
| 递延所得税负债 | 1,789,636.3 | 1,456,892.34 | 1,844,420.1 | 1,246,851.02 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 81,589,065.72 | 82,240,114.68 | 86,537,445.06 | 42,053,291.54 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 748,260,937.5 | 743,334,130.15 | 644,305,849.48 | 575,824,936.5 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 120,090,000 | 120,090,000 | 120,090,000 | 120,090,000 |
| 资本公积 | 1,444,304,706.77 | 1,444,304,706.77 | 1,444,048,725.94 | 1,444,048,725.94 |
| 减:库存股 | 54,309,920.07 | 1,592,630.81 | 525,952.67 | - |
| 专项储备 | 1,386,902.91 | 989,855.01 | 1,282,781.33 | 898,712.3 |
| 盈余公积 | 60,045,000 | 60,045,000 | 60,045,000 | 60,045,000 |
| 未分配利润 | 1,054,593,317.72 | 979,583,232.76 | 946,724,950.3 | 884,530,557.56 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,626,110,007.33 | 2,603,420,163.73 | 2,571,665,504.9 | 2,509,612,995.8 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,626,110,007.33 | 2,603,420,163.73 | 2,571,665,504.9 | 2,509,612,995.8 |
| 负债和股东权益合计 | 3,374,370,944.83 | 3,346,754,293.88 | 3,215,971,354.38 | 3,085,437,932.3 |
| 公告日期 | 2024-04-23 | 2024-04-23 | 2023-10-27 | 2023-08-18 |
| 审计意见(境内) | | 标准无保留意见 | | |